Assertio completes sale of six product franchises to Cosette for $35M cash plus up to $35M contingent payments

Assertio Holdings, Inc.

Products sold: INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, OTREXUP; deal closed April 8, 2026.
Upfront cash $35M; potential milestones up to $32M (SYMPAZAN, INDOCIN, OTREXUP) and SPRIX earn-out (quality approval $1M, 8% gross profits through 2027, $2M if 2027 net sales >$7M).
Pro forma continuing ops: 2025 net loss ~$31.3M (historical $30.4M); 2024 net loss ~$27.5M (historical $21.6M).
Estimated transaction costs ~$1.9M; estimated gain on disposal ~$16M.
Company also divested Assertio Therapeutics in May 2025; results removed from continuing ops in pro forma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.